Regulus Therapeutics focuses on developing therapeutics for patients with orphan kidney diseases, particularly targeting the underlying biology of these conditions with microRNA-based therapeutics.

Regulus Therapeutics

HSTS

Font Awesome

DNSSEC

Cloudflare CDN

Cloudflare

Microsoft

Gravity Forms

Lorem Ipsum

Cloudflare Bot Manager

Matomo

Chief Financial Officer

Cris Calsada

Chief Scientific Officer

Denis Drygin

President, CEO and Director

Jay Hagan

Co-Founder & CEO

Shoutian Zhu

Founder, CEO/CSO

Zhi Chu

Vice President, Business Development

Brian Campion

Vice President (Translational Medicine)

Edmund Lee

Vice President Clinical Development

Karl Cremer

Vice President, Biology

Morgan Carlson

Associate Director, Analytical Development

Daisy Khuu

Barry Greene

William Rastetter

Stelios Papadopoulos

Kathryn J. Collier

Peter S. Linsley

Simos Simeonidis

Director Board Of Directors

Mohammad Ahmadian

VP of Chemistry & Pharmaceutical Development

Amin Kamel

Vice President of DMPK

Greater San Diego Area Companies With Less Than $10M in Revenue (Top 10K)

California Therapeutics Companies

United States Public Companies With Less Than $1B in Revenue

Greater San Diego Area Companies With Less Than $500M in Revenue (Top 10K)

Regulus Therapeutics Is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. The discovery of MicroRNA in humans is one of the most exciting scientific breakthroughs in the last decade. MicroRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. 

It was founded in 2007 and is headquartered in Carlsbad, California.

Post-IPO Equity - Regulus Therapeutics

Federated Kaufmann Fund

New Enterprise Associates

Post-IPO Debt - Regulus Therapeutics

San Diego

California

United States

North America

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple ...

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

Regulus Therapeutics names Rekha Garg as chief medical officer

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 ...

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD (NASDAQ:RGLS)

Italy

Europe

India

Asia

HTML5

Lightbox

Adobe Fonts

GoDaddy Premium DNS

Vimeo

Google Fonts

Google Maps API

Apache Server

Wordpress

Office 365

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Regulus Therapeutics Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 30, 2024 12:49 PM	89b54647
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 30, 2024 12:49 PM	c913931b
crunchbase trigger	general	Oct 30, 2024 1:02 PM	aaabc096
crunchbase profile	general	Oct 31, 2024 6:50 AM	d92c571a
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	2217c4ff
peers	general	Sep 30, 2024 12:49 PM	f20e4f1d
news basic	general	Sep 30, 2024 12:49 PM	4421f7a6
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:REGULUSRX

Regulus Therapeutics

Last Close

1.40

22/11 21:00

Market Cap

115.22M

Beta: -

Volume Today

288.02K

Avg: -